MEDFORD, Mass., Oct. 4, 2016 /PRNewswire/ -- INVO Bioscience, Inc. (OTC: IVOB), a medical device company who was granted FDA clearance for the first Intravaginal Culture System, INVOcell™, today announced the launch of a new corporate website at www.invobioscience.com.
Katie Karloff, Chief Executive Officer of INVO Bioscience, commented, "INVO Bioscience has gone through a tremendous transformation following the FDA clearance of its device late last year. The revolutionary INVO Solution provides individuals struggling with infertility the opportunity to have access to an additional FDA Cleared option beyond the historical thirty plus year old traditional treatments such as Intrauterine Insemination (IUI) and In Vitro Fertilization (IVF). We look forward to providing a platform to provide information to doctors and patients across the United States to bring the affordable and accessible INVO Solution to the millions of individuals struggling with infertility problems with A Simpler Way to Life."
The INVO Solution is less expensive and in clinical studies has been proven to have equivalent efficacy and pregnancy success rates as traditional assisted reproductive techniques such as IVF and better chances of success than IUI. Additionally, the psychological benefits of direct participation with fertilization and early embryo development by vaginal incubation (in vivo), are incomparable to traditional IVF treatments. This new patented technique offers patients a more natural and personalized way to achieve pregnancy and is simple enough to be performed in an appropriately trained physician's office or in a satellite facility of an IVF center.
A SIMPLER WAY TO LIFE
The INVOcell is the first FDA cleared Intravaginal Culture (IVC) device and is a small polystyrene capsule used for egg fertilization and embryo development using vaginal incubation. In this technique, the woman's body is used as the natural incubator, laboratory incubators are only used to pre-warm media and disposable materials needed for the INVO Procedure. The advantage being the INVOcell utilizes the women's vagina as the main source of incubation. Couples participating in this treatment feel more directly involved, and more in control of the destiny of the embryo.
The INVO Procedure is a simpler technique where the patient undergoes natural or mild ovarian stimulation. Once the eggs are retrieved and the sperm is collected and prepared, they are immediately placed inside the INVOcell device which is then inserted into the woman's vaginal cavity where they will be incubated in vivo using the patient's body as a natural incubator. After several days, the INVOcell device is removed, the embryos are observed, selected and immediately transferred back to her body for further development and implantation.
INVO SOLUTION ADVANTAGES
For many struggling with infertility, access to treatment is often not possible. Financial challenges, limited availability of specialized medical care, religious, social and cultural roadblocks can prevent these hopeful parents from realizing their dream to have a baby.
There are many benefits to the INVO Solution. Here are just a few:
- Simpler procedure with natural or mild stimulation medication reducing the cost per cycle by approximately one half compared to traditional IVF.
- Reduces the risk of errors in embryo transfers or mishandling.
- Promotes greater involvement by couples in the treatment and conception.
- Creates a more natural and stable incubation than traditional IVF incubation in a laboratory.
- Reduces the worry of leaving embryos in an incubator where mix-ups have been known to occur.
With the INVO Solution, more and more patients can now receive safe, effective and affordable infertility treatment. To find a provider offering the INVO Solution please check our Partner Clinic Locations list or call (978) 878.9505 x503 or email us at email@example.com.
About INVO Bioscience
INVO Bioscience (IVOB) is a medical device company, headquartered in Medford, MA, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. The company's lead product, the INVOcell, is a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman's vaginal cavity. The company was founded by Claude Ranoux, MD, a noted expert in the field of reproductive health, infertility and embryology. For more information, please visit http://invobioscience.com/
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Kathleen Karloff, CEO INVO Bioscience, Inc. 978-878-9505 ext. 504
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/invo-bioscience-launches-new-corporate-website-300338537.html
SOURCE INVO Bioscience, Inc.